Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment
Abstract Background The emergence of targeted therapies and immunotherapy has broadened treatment options for patients with pancreatic ductal adenocarcinoma (PDAC). Despite this, traditional drug selection, predominantly relies on tumor markers and clinical staging, has underutilized these drugs due...
Saved in:
| Main Authors: | Peng Li, Minli Huang, Mengyao Li, Gen Li, Yifan Ma, Yong Zhao, Xiaowu Wang, Yongbin Zhang, Changhong Shi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-025-03332-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis
by: Yuan Fang, et al.
Published: (2024-11-01) -
Commentary: An insight to PDAC tumor heterogeneity across pancreatic subregions using computed tomography images
by: Jiandong Cao, et al.
Published: (2025-04-01) -
Small molecules enhance the high-efficiency generation of pancreatic ductal organoids
by: Liao Yuwei, et al.
Published: (2024-12-01) -
Obesity reprograms the normal pancreas and pancreatic cancer microbiome in mice and humans
by: Raquel Santana da Cruz, et al.
Published: (2025-07-01) -
Radiotherapy and immune microenvironment crosstalk in pancreatic cancer: a comprehensive review of current insights and future directions
by: Yucheng Xu, et al.
Published: (2025-07-01)